Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05746286 · ClinicalTrials.gov registry record · NA
Remote Monitoring of Vital Signs With Telehealth to Prevent Readmissions for Dysglycemia
A NA study, sponsored by DexCom.
- Completed
- Registry status
- NA
- Development phase
- 40
- Enrollment target
NCT05746286 is a NA study that has completed, run by DexCom. The registered enrollment target is 40 participants.
The verdict
NCT05746286, a NA study, has completed, sponsored by DexCom.
- COMPLETED
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
Study Summary
Patients who have experienced dysglycemia in hospital (either from diabetes, post-solid organ transplantation, medication titration, or other causes) may struggle to manage their blood glucose when discharged home. This may lead to ER visits or readmissions that could have been prevented if glucose variations were detected before reaching extremes, and the variations were contextualized with other vital sign parameters. Remote monitoring via Dexcom G6 and Current Health (vital signs) used concomitantly after discharged for the purpose of remote monitoring will be evaluated with respect to ER visits and readmissions while considering the impact and usability of the potential integrated system on the healthcare staff.
Interventions
- DEVICE Dexcom G6 CGM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2023-02-01 |
| Est. Completion | 2024-06-24 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05746286
The ClinicalTrials.gov registry entry for NCT05746286 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is DexCom, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dexcom G6 CGM is the first listed.
NCT05746286 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05746286 about?
NCT05746286 is a clinical study titled "Remote Monitoring of Vital Signs With Telehealth to Prevent Readmissions for Dysglycemia". Patients who have experienced dysglycemia in hospital (either from diabetes, post-solid organ transplantation, medication titration, or other causes) may struggle to manage their blood glucose when discharged home. This may lead to ER visits or readmissions that could have been prevented if glucose ...
What is the current status of trial NCT05746286?
This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2023-02-01. Estimated completion is 2024-06-24.
What interventions are being tested in trial NCT05746286?
The interventions under investigation include: Dexcom G6 CGM (DEVICE).
Who is sponsoring clinical trial NCT05746286?
This trial is sponsored by DexCom, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.